Amylyx reports Phase 3 win for GLP-1 antagonist avexitide in post-bariatric hypoglycemia

After a turbulent few years researching ALS, Amylyx Pharmaceuticals said it has notched a success in its attempt to rebuild as a GLP-1 biotech. A Phase 3 study for avexitide, a GLP-1 receptor antagonist, hit ...